Becotatug Vedotin (MRG003)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Becotatug Vedotin (MRG003), covering 2026-04-02 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 3]